BGHL (EUR): NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
23
BGHL (EUR): NAV(s)

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

Close of business 08 Feb 2019.

Estimated NAV

  Euro Shares Sterling Shares
Estimated NAV €  21.9651 £  19.6385
Estimated MTD return  0.18 %  0.20 %
Estimated YTD return  -0.18 %  -0.03 %
Estimated ITD return  119.65 %  96.39 %

NAV and returns are calculated net of management and performance fees

Market information

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  17.00 N/A
Premium/discount to estimated NAV  -22.60 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,500.00
Premium/discount to estimated NAV N/A  -23.62 %

Transactions in own securities purchased into treasury

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

           

                                           

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

BGHL Capital

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,782,231  608,712
Held in treasury N/A N/A
Shares Issued  28,782,231  608,712

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  179.1868

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

  • all investment is subject to risk;
  • results in the past are no guarantee of future results;
  • the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and
  • if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 6

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading

Top 5 Most Recently Viewed Articles

PMGC Capital's Strategic Investment in Alaunos Therapeutics

Updated Category News Views 171

PMGC Capital LLC Plans to File Schedule 13D on Alaunos PMGC Capital LLC, a fully owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has made a significant move in the financial landscape by announcing its intention to file a Schedule 13D with the U.S. Securities and Exchange Commission (SEC). This filing will disclose its beneficial ownership in Alaunos Therapeutics,...

Continue Reading
Black Diamond Therapeutics: Pivotal Developments Ahead

Updated Category News Views 97

Black Diamond Therapeutics Continues to Make Strides Recently, H.C. Wainwright confirmed a Buy rating on Black Diamond Therapeutics (NASDAQ: BDTX) shares, projecting a price target of $11.00. This positive outlook follows the company's major restructuring efforts aimed at advancing BDTX-1535, its leading drug candidate, into pivotal trials. This move is expected to not...

Continue Reading
Eureka Acquisition Corp Announces New Meeting Date and Deadlines

Updated Category News Views 187

Eureka Acquisition Corp's Important Announcement New York — Eureka Acquisition Corp (NASDAQ: EURK), a special purpose acquisition company, has recently made significant announcements regarding the schedule of its extraordinary general meeting. Originally set for June 20, it will now take place on June 25, providing shareholders with extra time for participation. Details...

Continue Reading
Diamedica Therapeutics Hits New Heights with $6.41 Stock Value

Updated Category News Views 118

Diamedica Therapeutics Inc. Achieves 52-Week High Diamedica Therapeutics Inc. (NASDAQ: DMAC) is making headlines as its stock has recently hit a remarkable 52-week high of $6.41. This impressive milestone comes amid a significant growth phase for the company, which is currently valued at around $230 million. The steep rise in the stock price over the past year indicates a...

Continue Reading
J.P. Morgan's Projections for 2025: Capital Market Insights

Updated Category News Views 6083

J.P. Morgan's Capital Market Assumptions for 2025 J.P. Morgan Asset Management has recently unveiled its 2025 Long-Term Capital Market Assumptions (LTCMAs), providing valuable insights into the anticipated returns and risks across various asset classes for the next decade. These projections serve as a compass for investment strategies, targeting institutional and...

Continue Reading